The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …

Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …

It is more than 50 years since the Epstein–Barr virus (EBV), the first human tumour virus, was
discovered. EBV has subsequently been found to be associated with a diverse range of …

Epidemiological trends during the past decade suggest that although incidence of
nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from …

As a consequence of the current excellent loco-regional control rates attained using the
generally accepted treatment paradigms involving intensity-modulated radiotherapy for …

Nasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China,
and patient prognosis has improved significantly over the past three decades because of …

The clinical benefit of therapeutic cancer vaccines has been established. Whereas
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …

Epstein-Barr virus (EBV) is usually acquired silently early in life and carried thereafter as an
asymptomatic infection of the B lymphoid system. However, many circumstances disturb the …

Nasopharyngeal carcinoma (NPC) is a metastasis-prone malignancy closely associated
with the Epstein–Barr virus (EBV). Despite ubiquitous infection of EBV worldwide, NPC …